Aceon: Advanced Blood Pressure Control with Perindopril
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.71 | $51.21 (0%) | 🛒 Add to cart |
| 60 | $1.37 | $102.41 $82.33 (20%) | 🛒 Add to cart |
| 90 | $1.26 | $153.62 $113.46 (26%) | 🛒 Add to cart |
| 120 | $1.20 | $204.83 $143.58 (30%) | 🛒 Add to cart |
| 180 | $1.14 | $307.24 $205.83 (33%) | 🛒 Add to cart |
| 270 | $1.10 | $460.87 $298.21 (35%) | 🛒 Add to cart |
| 360 | $1.08
Best per pill | $614.49 $389.58 (37%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.91 | $57.23 (0%) | 🛒 Add to cart |
| 60 | $1.52 | $114.46 $91.37 (20%) | 🛒 Add to cart |
| 90 | $1.37 | $171.69 $123.50 (28%) | 🛒 Add to cart |
| 120 | $1.31 | $228.93 $157.64 (31%) | 🛒 Add to cart |
| 180 | $1.24 | $343.39 $223.91 (35%) | 🛒 Add to cart |
| 270 | $1.20
Best per pill | $515.08 $324.31 (37%) | 🛒 Add to cart |
| Product dosage: 8mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.88 | $86.35 (0%) | 🛒 Add to cart |
| 60 | $2.28 | $172.70 $136.55 (21%) | 🛒 Add to cart |
| 90 | $2.09 | $259.05 $187.76 (28%) | 🛒 Add to cart |
| 120 | $1.99 | $345.40 $238.97 (31%) | 🛒 Add to cart |
| 180 | $1.89 | $518.10 $339.37 (34%) | 🛒 Add to cart |
| 270 | $1.83
Best per pill | $777.15 $493.00 (37%) | 🛒 Add to cart |
Synonyms
| |||
Aceon (perindopril erbumine) is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents. It is also approved for the reduction of cardiovascular risk in patients with stable coronary artery disease. This medication works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in decreased vascular resistance and blood pressure. Clinical evidence supports its efficacy in improving endothelial function and reducing left ventricular hypertrophy, offering both hemodynamic and structural benefits to patients with cardiovascular conditions.
Features
- Active ingredient: Perindopril erbumine
- Drug class: Angiotensin-converting enzyme (ACE) inhibitor
- Available strengths: 2 mg, 4 mg, and 8 mg tablets
- Administration: Oral, once-daily dosing
- Mechanism: Inhibits ACE, reducing angiotensin II formation and aldosterone secretion
- Bioavailability: Approximately 75% following oral administration
- Half-life: Effective half-life ranges from 3-10 hours
- Excretion: Primarily renal (75%) with some fecal elimination
Benefits
- Effectively lowers systolic and diastolic blood pressure through vasodilation
- Reduces afterload on the heart, decreasing myocardial oxygen demand
- Demonstrates cardioprotective effects by regressing left ventricular hypertrophy
- Improves endothelial function and vascular compliance
- Shows proven cardiovascular risk reduction in patients with established coronary artery disease
- Offers once-daily dosing convenience with consistent 24-hour blood pressure control
Common use
Aceon is primarily prescribed for the management of essential hypertension in adults. It is frequently used as first-line therapy, particularly in patients who may benefit from ACE inhibition due to comorbid conditions such as diabetes mellitus, chronic kidney disease, or heart failure. The medication is also indicated for cardiovascular risk reduction in patients with stable coronary artery disease, including those who have undergone revascularization procedures. Clinical practice often incorporates Aceon into combination therapy regimens with thiazide diuretics or calcium channel blockers when monotherapy provides insufficient blood pressure control.
Dosage and direction
The recommended initial dosage for hypertension treatment is 4 mg once daily, which may be increased to 8 mg once daily after at least two weeks of therapy based on blood pressure response. For elderly patients or those with renal impairment, starting with 2 mg once daily is advised. Patients should take Aceon at approximately the same time each day, with or without food, though consistency in administration relative to meals is recommended. Tablets should be swallowed whole with a glass of water and not crushed or chewed. Dosage adjustments should be made gradually, with blood pressure monitoring before and after dosage changes. For cardiovascular risk reduction in stable coronary artery disease, the recommended maintenance dose is 8 mg once daily, though therapy should be initiated at 4 mg once daily for two weeks before increasing to the target dose.
Precautions
Patients should be monitored for hypotension, especially during initial therapy and following dosage increases. Renal function should be assessed before initiation and periodically during treatment, particularly in patients with pre-existing renal impairment, heart failure, or volume depletion. Serum potassium levels require monitoring, especially in patients receiving concomitant potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium. Aceon may cause angioedema, which can occur at any time during treatment and requires immediate discontinuation if involvement of the tongue, glottis, or larynx occurs. Patients with collagen vascular disease or those receiving immunosuppressive therapy may be at increased risk for hematologic reactions. The medication should be used with caution in patients undergoing major surgery or during anesthesia due to potential hypotension.
Contraindications
Aceon is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy. It should not be used in patients with hereditary or idiopathic angioedema. The medication is contraindicated during pregnancy, particularly in the second and third trimesters, due to the risk of fetal injury and death. Concomitant use with aliskiren in patients with diabetes is contraindicated. Patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney should not receive Aceon. Hypersensitivity to perindopril or any component of the formulation constitutes an absolute contraindication.
Possible side effects
The most commonly reported adverse reactions include cough (12%), dizziness (8%), headache (5%), and fatigue (3%). Gastrointestinal effects such as nausea, diarrhea, and abdominal pain occur in approximately 2-3% of patients. Rash and taste disturbance have been reported in less than 2% of cases. More serious but less frequent side effects include angioedema (0.1-0.5%), hyperkalemia (2%), and renal impairment (1-2%). Hypotension may occur, particularly in volume-depleted patients. Rare cases of neutropenia, agranulocytosis, and hepatic enzyme elevations have been reported. Patients should be advised that the characteristic dry cough associated with ACE inhibitors may develop at any time during therapy and typically resolves upon discontinuation.
Drug interaction
Concomitant use with diuretics may potentiate the hypotensive effect, particularly following the first dose. Nonsteroidal anti-inflammatory drugs (NSAIDs) may diminish the antihypertensive effect and increase the risk of renal impairment. Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia. Concurrent use with lithium may decrease lithium clearance and increase lithium toxicity risk. Aceon may increase blood concentrations of mTOR inhibitors such as everolimus and temsirolimus. Dual blockade of the renin-angiotensin system with ARBs or aliskiren increases the risk of hypotension, hyperkalemia, and renal impairment. Antidiabetic medications may require dosage adjustment as Aceon could enhance their hypoglycemic effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistency in daily dosing is important for maintaining stable blood pressure control, so patients should be advised to establish a routine for medication administration. If multiple doses are missed, blood pressure should be monitored closely and the healthcare provider consulted for guidance on resuming therapy.
Overdose
Symptoms of overdose primarily involve hypotension, which may be severe and accompanied by bradycardia, circulatory shock, electrolyte disturbances, and renal failure. Management should include supportive measures with emphasis on correcting hypotension through volume expansion with intravenous normal saline. Vasopressor therapy may be required in severe cases. Perindopril is not effectively removed by hemodialysis due to extensive tissue binding. Patients should be monitored for electrolyte imbalances and renal function. Gastric lavage may be considered if ingestion occurred recently, and activated charcoal may be administered though its efficacy in ACE inhibitor overdose is not well established.
Storage
Aceon tablets should be stored at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be kept in its original container with the lid tightly closed to protect from moisture and light. Tablets should not be stored in bathroom cabinets or other areas with high humidity. Keep out of reach of children and pets. Do not use tablets that show signs of discoloration, cracking, or other physical deterioration. Proper disposal of expired or unused medication should follow local regulations, typically through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Aceon is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual patient responses may vary, and therapeutic decisions should be based on the healthcare provider’s assessment of the specific clinical situation. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions. Patients should consult their healthcare provider for complete information about their medication regimen and report any adverse effects promptly.
Reviews
Clinical studies demonstrate that Aceon provides effective 24-hour blood pressure control with once-daily dosing. In the EUROPA trial, perindopril significantly reduced cardiovascular events in patients with stable coronary artery disease. Many clinicians report satisfactory blood pressure control in diverse patient populations, though the characteristic ACE inhibitor cough remains a common reason for discontinuation. Patients who tolerate the medication generally report consistent blood pressure management with minimal disruption to daily activities. The medication’s cardioprotective effects beyond blood pressure lowering are particularly valued in patients with established cardiovascular disease. Some practitioners note the need for careful dose titration in elderly patients and those with renal impairment to avoid excessive hypotension.